Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension
Primary Purpose
Sleep Apnea, Hypertension
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Autotitrating Positive Airway Pressure (APAP)
Traditional Split Titration Polysomnogram
Sponsored by
About this trial
This is an interventional treatment trial for Sleep Apnea focused on measuring Sleep Disordered Breathing, Sleep Apnea, Hypertension, Continuous Positive Airway Pressure
Eligibility Criteria
Inclusion Criteria:
- Subjects who are competent to provide written consent
- Aged 18 to 80 years
- Deemed to be compliant with anti-hypertension medication therapy.
- Subjects with diabetes and/or chronic kidney disease must have a mean 24 hour systolic blood pressure ≥130 mmHg
- All other subjects must have a mean 24 hour systolic blood pressure ≥140 mmHg
- Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, preferably including a diuretic
Exclusion Criteria:
- Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
- Known Sleep apnea
- Subjects who perform alternating shift or night work
- Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening
- Have hypertension secondary to an identifiable and treatable cause other than sleep apnea
Subjects taking over the counter medications that can raise blood pressure, such as
- Non narcotic analgesics
- Non steroidal anti-inflammatory agents, including aspirin, Selective COX-2 inhibitors
- Sympathomimetic agents (decongestants, diet pills, cocaine)
- Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, methamphetamine, modafinil)
- Alcohol
- Oral contraceptives
- Cyclosporine
- Erythropoietin
- Natural licorice
- Herbal compounds (ephedra or ma huang)
Sites / Locations
- Albert Einstein Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Ambulatory APAP and SMT
Titration Polysomnogram with CPAP and SMT
Arm Description
Subjects placed on the APAP machine
Subjects placed on CPAP machine
Outcomes
Primary Outcome Measures
Noninferiority of the change from baseline to 90 day measurement in mean ambulatory 24-hour systolic ambulatory blood pressure in the Newer approach v/s Traditional Approach
Secondary Outcome Measures
Noninferiority of the change from baseline to 90 day measurement in mean ambulatory 24-hour diastolic ambulatory blood pressure in the Newer approach v/s Traditional Approach
Full Information
NCT ID
NCT00973531
First Posted
September 2, 2009
Last Updated
January 25, 2012
Sponsor
Albert Einstein Healthcare Network
1. Study Identification
Unique Protocol Identification Number
NCT00973531
Brief Title
Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension
Official Title
Effect of Treating Sleep Disorder Breathing Therapy in Patients With Resistant Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Withdrawn
Study Start Date
May 2009 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Albert Einstein Healthcare Network
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators would like to investigate the effects of treating sleep apnea with a positive airway pressure device, either continuous (titrated) versus auto titrated on the control of blood pressure in patients with Resistant Hypertension.
Detailed Description
One of the major cause and contributor to stroke, myocardial infarction, heart disease, and kidney disease is high blood pressure. Traditional approaches to control of hypertension (HTN) have mostly included pharmaceuticals targeting different mechanisms that contribute to HTN. However, adequate control of Blood pressure continues to remain a major problem.
Sleep Apnea is currently being recognized as a modifiable risk factor for resistant HTN. Sleep disordered breathing represents states of increased sympathetic drive and vagal tone withdrawal, along with significant episodic hypoxia. There is increasing evidence that sleep apnea is highly prevalent in subjects with hypertension and may be a frequent cause of drug-resistant hypertension.
We propose that we compare strategies for treating subjects with Resistant Hypertension who have SDB as detected by ambulatory multi somnogram and treat subjects using:
Ambulatory Autotitrating Positive Airway Pressure (APAP) plus Standard medical therapy OR
Traditional Polysomnogram and Traditional PSG guided titration of Continuous Positive Airway Pressure (CPAP) plus Standard medical therapy
Our hypothesis is that in subjects with Resistant HTN, who have SDB, using the treatment approach of ambulatory multisomnography for testing and then treating with APAP will be noninferior to the traditional polysomnography plus CPAP approach in the amount of reduction of mean systolic and diastolic 24 hour ambulatory blood pressure, when treated for 90 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Hypertension
Keywords
Sleep Disordered Breathing, Sleep Apnea, Hypertension, Continuous Positive Airway Pressure
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ambulatory APAP and SMT
Arm Type
Other
Arm Description
Subjects placed on the APAP machine
Arm Title
Titration Polysomnogram with CPAP and SMT
Arm Type
Other
Arm Description
Subjects placed on CPAP machine
Intervention Type
Device
Intervention Name(s)
Autotitrating Positive Airway Pressure (APAP)
Intervention Description
Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
Intervention Type
Device
Intervention Name(s)
Traditional Split Titration Polysomnogram
Intervention Description
Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
Primary Outcome Measure Information:
Title
Noninferiority of the change from baseline to 90 day measurement in mean ambulatory 24-hour systolic ambulatory blood pressure in the Newer approach v/s Traditional Approach
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Noninferiority of the change from baseline to 90 day measurement in mean ambulatory 24-hour diastolic ambulatory blood pressure in the Newer approach v/s Traditional Approach
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects who are competent to provide written consent
Aged 18 to 80 years
Deemed to be compliant with anti-hypertension medication therapy.
Subjects with diabetes and/or chronic kidney disease must have a mean 24 hour systolic blood pressure ≥130 mmHg
All other subjects must have a mean 24 hour systolic blood pressure ≥140 mmHg
Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, preferably including a diuretic
Exclusion Criteria:
Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg
Known Sleep apnea
Subjects who perform alternating shift or night work
Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening
Have hypertension secondary to an identifiable and treatable cause other than sleep apnea
Subjects taking over the counter medications that can raise blood pressure, such as
Non narcotic analgesics
Non steroidal anti-inflammatory agents, including aspirin, Selective COX-2 inhibitors
Sympathomimetic agents (decongestants, diet pills, cocaine)
Stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, amphetamine, methamphetamine, modafinil)
Alcohol
Oral contraceptives
Cyclosporine
Erythropoietin
Natural licorice
Herbal compounds (ephedra or ma huang)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Darshak Karia, MD
Organizational Affiliation
Albert Einstein Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Albert Einstein Medical Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19141
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension
We'll reach out to this number within 24 hrs